# Recida Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/recida-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Menlo Park, US
- Website: www.recidatherapeutics.com
- Total disclosed funding: $8.5M
- Latest round: Series A (Feb 6, 2019)
- Investors on record: 1

## About

Founded in 2016 and based in California, US, Recida Therapeutics, Inc. is a biopharmaceutical company that develops anti-infective medicines for multi-drug resistant infections. The company's program RC-01, an IND-stage LpxC inhibitor to treat multidrug-resistant gram-negative infections. RC-01 prevents bacterial LpxC, an enzyme in Lipid A biosynthesis, which is an essential component of the outer membrane of gram-negative bacteria for its survival.

## Funding rounds

- Series A, Feb 6, 2019, $8.5M — Frazier Healthcare Partners

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A